Clinical Trials
22 trialsNCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06066359 2026-05-13
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06615479 2026-05-13
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT05020444 2026-05-12
TriPRIL CAR T Cells in Multiple Myeloma
Massachusetts General Hospital
Phase 1 Recruiting
NCT07149857 2026-05-08
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06413498 2026-05-07
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05909059 2026-04-20
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
Phase 2 Recruiting
NCT03710421 2026-04-15
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
City of Hope Medical Center
Phase 1 Recruiting
NCT06153251 2026-03-18
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1 Recruiting
NCT07340853 2026-03-10
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT06940297 2026-02-06
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT05031897 2025-10-30
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
Phase 2 Recruiting
NCT03016806 2025-10-10
Umbilical Cord Blood Transplantation From Unrelated Donors
University of Rochester
Recruiting
NCT05722418 2025-09-25
CaMMouflage
Caribou Biosciences, Inc.
Phase 1 Recruiting
NCT05805605 2025-07-01
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT04561557 2024-10-30
CARTinNS
Tongji Hospital
Phase EARLY_PHASE1 Recruiting
NCT05998928 2023-11-13
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT05528887 2022-09-06
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase 1 Recruiting